Analyst firms · Leerink Partners · GOSS

Leerink Partners GOSS price target and rating history

Gossamer Bio Inc. (GOSS) · Health Care

Leerink Partners rates Gossamer Bio Inc. (GOSS) Outperform with a $1 price target, as of its latest action on Jul 28, 2026. It has published 4 rating actions on GOSS since August 2021, including 1 upgrade and 1 downgrade. Across 4 firms with a GOSS price target in the last 12 months, the median target is $1. Leerink Partners's target matches it.

Current rating
Outperform
Price target
$1
Median target, all firms
$1
Actions on GOSS
4

Leerink Partners price target on GOSS

$16$8.50$120222023202420252026
Leerink Partners price target on GOSS, each point a stated target, August 2021 to July 2026.

Every Leerink Partners rating on GOSS

How other firms rate GOSS

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Chardan Capital MarketsBuy$160Oct 13, 2026
Leerink PartnersOutperform$1Jul 28, 2026
Cantor FitzgeraldNeutralMar 23, 2026
WedbushNeutral$1Feb 24, 2026
BarclaysEqual Weight$0.30Feb 24, 2026

Questions about Leerink Partners and GOSS

What is Leerink Partners's price target for GOSS?
Leerink Partners's latest stated price target for Gossamer Bio Inc. (GOSS) is $1, from its action on Jul 28, 2026.
What is Leerink Partners's rating on GOSS?
Leerink Partners rates GOSS Outperform, a bullish rating, as of Jul 28, 2026.
When did Leerink Partners last change its view on GOSS?
On Jul 28, 2026, Leerink Partners upgrades to Outperform from Market Perform, price target $1.
How does Leerink Partners's GOSS target compare with other analysts?
Across 4 firms with a GOSS price target in the last 12 months, the median target is $1. Leerink Partners's target matches it.

More GOSS rating histories

All Leerink Partners ratingsGOSS news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.